Table 1. Baseline characteristics and clinical outcomes for mother-infant pairs.
| Probiotic group (n = 32) | Placebo group (n = 22) | |
|---|---|---|
| Mother-infant pair baseline characteristics: | ||
| Age, mother (years), mean (SD) | 30.51 (4.17) | 31.18 (4.44) |
| Gestational age (days), mean (SD) | 283.1 (10.51) | 281.2 (14.54) |
| Birth weight (g), mean (SD) | 3581 (402) | 3537 (449) |
| Gender (male), n (%) | 18 (56.3) | 10 (45.5) |
| Premature a , n (%) | 0 (0.0) | 2 (9.5) b |
| No siblings, n (%) | 17 (53.1) | 13 (59.1) |
| Atopy in family, n (%) | 19 (59.4) | 16 (72.7) b |
| Maternal atopy, n (%) | 11 (34.4) | 14 (63.6) |
| Post-randomisation characteristics b : | ||
| Breastfeeding | ||
| At least 3 mo., n (%) | 31 (96.9) | 21 (100) |
| Duration exclusive, mo., med (range) | 4 (0–7) | 5 (1–8) |
| Age of weaning, mo., med (range) | 12 (2–24) | 11 (4–22) |
| Sample collection, days (SD) | 89.5 (8.1) | 93.7 (15.5) |
| Age of samples, years (SD) | 8.4 (0.6) | 8.5 (0.6) |
| Infant clinical outcomes at 2 years of age: | ||
| Atopic dermatitis, n (%) | 11 (34.4) | 18 (81.8) |
| IgE associated, n (%) | 5 (15.6) | 3 (13.6) |
| Non-IgE associated, n (%) | 6 (18.8) | 14 (63.6) |
| Sensitisation, n (%) | 7 (21.9) | 3 (13.6) |
| Asthma, n (%) | 2 (6.3) | 2 (9.1) |
| Allergic rhinitis, n (%) | 1 (3.1) | 0 (0.0) |
aDefined as birth before 37 weeks gestation
bmissing information for some individuals